1SUMMERS J, MASON W S. Replication of the genome of a hepatitis B -like virus by revere transcription of an RNA intermediate[J]. Cell, 1982, 29(2): 403-415.
2BOCK C T, TILLMANN H, TORRESI J, et al. Selection of hepatitis B virus polymcrase mutants with enhanced replication by lamivudine treatment after liver transplantation [ J]. Gastroenterology, 2002, 122(2) : 264 -273.
4SUNG J J, WONG M L, BOWDEN S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy[ J ]. Gastroenterology, 2005, 128 (7) : 1890 - 1897.
5GIRONES R, MILLER R H. Mutation rate of the hepadnavirus genome[J]. Virology, 1989, 170(2) : 595 -597.
6NOWAK M A, BONHOEFFER S, HILL A M, et al. Viral dynamics in hepatitis B virus infection[ J]. Proc Natl Acad Sci USA, 1996, 93(9) : 4398 -4402.
7LITWIN S, TOLL E, JILBERT A R, et al. The competing roles of vires replication and hepatoeyte death rates in the emergence of drug - resistant mutants: theoretical considerations [ J ]. J Clin Virol, 2005, 34(Suppl 1 ):S96- S107.
8LOK A S, ZOULIM F, LOCARNINI S, et al. Antiviral drug - resistant HBV: standardization of nomenclature and assays and recommendations for management [J].Hepatology, 2007, 46 ( 1 ) : 254 - 265.
9RICHMAN D D. The implications of drug resistance for strategies of combination antiviral chemotherapy [ J ]. Antiviral Res, 1996, 29(1): 31 -33.
10VILLET S, PICHOUD C, BILLIOUD G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure [ J ]. J Hepatol, 2008, 48 (5) : 747 - 755.
二级参考文献10
1Chin R, Shaw T, Torresi J, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl- beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother,2001,45:2495-2501.
2Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology,2001,33:751-757.
3Delaney WE, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother,2001,12:1-35.
4Ogata N, Fujii K, Takigawa S, et al. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B. J Med Virol,1999,59:270-276.
5Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology,2003,125:292-297.
6Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology,2001,33:1527-1532.
7Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology,1999,30:567-572.
8Sun J, Wang Z, Ma S, et al. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience. J Med Virol,2005,75:391-398.
9Xiong X, Flores C, Yang H, et al. Mutations in hepatitis B DNA polymerase asssociated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology, 1998,28:1669-1673.
10Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology,2004,126:91-101.
